Drug Discovery & Development | Q&As & Interviews
Addressing Immunotherapy Resistance Through PVRIG And TIGIT Blockade
21 July 2022
In this interview, Eran Ophir discusses Compugen's exciting approach to immune checkpoint inhibitors for the treatment of cancer and what makes them stand out from the crowd.
Speaker Biographies
Dr. Eran Ophir was appointed Senior Vice President of Research and Drug Discovery in April 2022. In his role, Eran is responsible for the company’s scientific strategy, overseeing the research and drug discovery activities, including research into the biology of the company’s computationally discovered targets, biomarkers and translational research and therapeutic lead antibody identification and selection. Eran brings significant expertise in immunology and immuno-oncology from his research work at the Weizmann Institute of Science and the Ludwig Institute for Cancer Research in Lausanne, Switzerland. Eran joined Compugen in 2015 as a senior scientist and has since held various positions in the R&D department, with increasing responsibilities including appointment to the management team in March 2020. Eran received a B.Sc. in Bioinformatics from Tel Aviv University and a Ph.D. in Biology from the Weizmann Institute of Science
Subscribe to our newsletter
Sign up for our monthly Newsletter to keep up with all things NextGen Biomed